Please visit answersincme.com/MDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the impact of adjuvant immune checkpoint inhibitors (ICIs) on outcomes in patients with resected early-stage non-small cell lung cancer (NSCLC), and how to optimally integrate them into practice based on recent evidence. Upon completion of this activity, participants should be better able to: Review guideline-recommended adjuvant treatment options for patients with surgically resected early-stage NSCLC; Describe the clinical evidence for novel ICIs being investigated for the adjuvant treatment of surgically resected early-stage NSCLC; and Outline clinical considerations for the use of novel adjuvant ICIs in the management of patients with surgically resected early-stage NSCLC.